Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases

Steinbach, William J.; Benjamin Jr., Daniel K.; Kontoyiannis, Dimitrios P.; Perfect, John R.; Lutsar, Irja; Marr, Kieren A.; Lionakis, Michail S.; Torres, Harrys A.; Jafri, Hasan; Walsh, Thomas J.
July 2004
Clinical Infectious Diseases;7/15/2004, Vol. 39 Issue 2, p192
Academic Journal
Current in vitro and in vivo data indicate that invasive aspergillosis due to Aspergillus terreus is resistant to treatment with amphotericin B. Because little clinical data are available to guide therapy, we performed a retrospective cohort study of cases of invasive A. terreus infections from 1997-2002 to determine whether the use of voriconazole, compared with use of other antifungal therapies, led to an improved patient outcome. We analyzed a total of 83 cases of proven or probable invasive A. terreus infection (47% and 53%, respectively). A total of 66.3% of patients (55 of 83) died during management of IA, with 55.8% mortality (19 of 34 patients) in the voriconazole group and 73.4% mortality (36 of 49) in the group that received therapy with other antifungals. By use of Cox proportional hazards modeling, decreased mortality at 12 weeks was observed in those patients who received voriconazole (hazard ratio, 0.29; 95% CI, 0.15-0.56). Voriconazole is likely to be a better treatment choice for A. terreus infection than is a polyene.


Related Articles

  • A FOCUS ON NEW BIOMARKERS OF ASPERGILLUS AS A DIAGNOSTIC TARGET IN INVASIVE ASPERGILLOSIS. Hedayati, Mohammad Taghi // Jundishapur Journal of Microbiology;2013 Special Edition, p2 

    Invasive aspergillosis (IA) is a clinical form due to Aspergillus and a major cause of morbidity and mortality in the severely immunocompromised patients. The diagnosis of IA is still a great challenge in immunocompromised patients, and it is often made late in the course of the infection. The...

  • Combination Therapy for Invasive Aspergillosis. Viscoli, Claudio // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p803 

    The article discusses the combination therapy for invasive aspergillosis. Mortality in patients with invasive aspergillosis remains unacceptably high, particularly in the subgroup of patients receiving hematopoietic stem cell transplants. For this reason, when caspofungin and voriconazole, which...

  • Molecular Mechanisms of Aspergillus Resistance to Antifungals. Ruoyu Li; Wei Liu; Jianjun Qiao; Jian Chen; Houmin Li // Japanese Journal of Medical Mycology;2007 Supplement, Vol. 48, p42 

    The article reports on the results of a study on the molecular mechanisms of aspergillus resistance to antifungals. Aspergillus species are considered the major cause of aspergillosis. The article discusses the characteristics and treatment of diseases caused by aspergillus. The study revealed...

  • Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Clemons, Karl V.; Stevens, David A. // Medical Mycology;Feb2006, Vol. 44 Issue 1, p69 

    Mortality from invasive pulmonary aspergillosis approaches 80% with few useful therapeutic options available. In these studies, we examined the efficacy of micafungin (MICA) alone or in combination with other antifungals in a model of pulmonary aspergillosis in immunosuppressed DBA/2 mice...

  • Exacerbation of invasive aspergillosis by the immunosuppressive fungal metabolite, gliotoxin. Sutton, Philip; Waring, Paul; Müllbacher, Arno // Immunology & Cell Biology;Aug1996, Vol. 74 Issue 4, p318 

    Invasive aspergillosis is a significant cause of death in immunocompromised individuals. The majority of strains of the main causative agent, Aspergillus fumigatus, produce gliotoxin, a secondary metabolite with demonstrated in vitro immunosuppressive activity. Pretreatment of normally resistant...

  • Combination Antifungal Therapy for Invasive Aspergillosis. Marr, Kieren A.; Boeckh, Michael; Carter, Rachel A.; Hyung Woo Kim; Corey, Lawrence // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p797 

    Background. Asp ergillosis therapy with amphotericin, azoles, or echinocandins is associated with substantial mortality, ranging from 30% to 80%, depending on the stage of infection and the host's underlying disease. Th results of in vitro studies and animal models suggest that combination...

  • Comparison between Aspergillus fumigatus conidia and hyphae susceptibilities to amphotericin B, itraconazole, and voriconazole by use of the mold rapid susceptibility assay. Wetter, Tracy J.; Hazen, Kevin C.; Cutler, Jim E. // Medical Mycology;Sep2005, Vol. 43 Issue 6, p525 

    Although hyphae are the morphological form observed in tissue during invasive Aspergillus fumigatus infections, antifungal susceptibility testing for A. fumigatus utilizes conidial inocula. Previous studies have yielded conflicting results as to whether conidia adequately reflect antifungal...

  • Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. R. Y. Hachem; A. A. Langston; J. R. Graybill; J. R. Perfect; L. D. Pedicone; H. Patino; I. I. Raad // Journal of Antimicrobial Chemotherapy (JAC);Dec2008, Vol. 62 Issue 6, p1386 

    : Objectives The aim of this study is to determine the efficacy and safety of posaconazole in patients with underlying renal impairment. : Patients and methods We analysed the efficacy and safety of posaconazole in patients with renal impairment in a post hoc subanalysis of a Phase 3,...

  • Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Böhme, Angelika; Ruhnke, Markus; Buchheidt, Dieter; Cornely, Oliver; Einsele, Herrmann; Enzensberger, Ruxandra; Hebart, Holger; Heinz, Werner; Junghanss, Christian; Karthaus, Meinolf; Krüger, William; Krug, Utz; Kubin, Thomas; Penack, Olaf; Reichert, Dietmar; Reuter, Stefan; Silling, Gerda; Südhoff, Thomas; Ullmann, Andrew; Maschmeyer, Georg // Annals of Hematology;Feb2009, Vol. 88 Issue 2, p97 

    Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics